<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351400</url>
  </required_header>
  <id_info>
    <org_study_id>PB3170012</org_study_id>
    <nct_id>NCT03351400</nct_id>
  </id_info>
  <brief_title>Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration</brief_title>
  <acronym>JOKER</acronym>
  <official_title>Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sakakibara Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CellBank of Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sakakibara Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of intracoronary
      infusion of autologous cardiac stem cells in patients with ischemic cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase I trial will involve 6 patients suffering from chronic ischemic cardiomyopathy and
      congestive heart failure, to be compared with historical control subjects. This study will be
      conducted as a collaborative project between the Sakakibara Heart Institute and the CellBank
      of Japan. The trial is designed to assess the safety and effectiveness of autologous
      administration of 1,000,000 c-kit-positive cardiac stem cells (CSCs) via intracoronary route
      following cultivation. The preliminary eligibility criteria will utilize a left ventricular
      ejection fraction (LVEF) less than 40% measured by echocardiography. During the coronary
      artery bypass grafting (CABG) surgery, a part (less than 1 gram) of the right atrial
      appendage (RAA) will be harvested and frozen. When the LVEF is less than 40% after the CABG
      surgery, the subject will be enrolled as a candidate for the delivery of CSCs, which will be
      selected from the RAA tissue and cultured for a few months for expansion. The outcome will be
      evaluated by adverse events as well as cardiac functions.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monitoring adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Including death, ventricular arrhythmia, bleeding, myocardial infarction, cardiac tumor, brain stroke, peripheral embolism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA classification</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of symptom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum NT-proBNP</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of cardiac function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of arrhythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest X-ray</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of cardiac function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary exercise test</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of cardiopulmonary function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of cardiac function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance imaging</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of cardiac function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial scintigraphy</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of myocardial viability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Old Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem cells administered to participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem cells administered to participants</intervention_name>
    <description>Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult with ability to provide informed consent.

          -  Left ventricular ejection fraction less than 40% as evidenced by echocardiogram.

          -  Scheduled for elective surgical revascularization within 2 months.

        Exclusion Criteria:

          -  Positive for HBs-Ag, HCV-Ab, HIV-Ab, or tests for syphilis.

          -  Diabetic HbA1c greater than 8.5%.

          -  Pregnant women.

          -  Scheduled for additional interventions including ventriculoplasty.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sakakibara Heart Institute</name>
      <address>
        <city>Tokyo</city>
        <zip>183-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Chugh AR, Beache GM, Loughran JH, Mewton N, Elmore JB, Kajstura J, Pappas P, Tatooles A, Stoddard MF, Lima JA, Slaughter MS, Anversa P, Bolli R. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012 Sep 11;126(11 Suppl 1):S54-64.</citation>
    <PMID>22965994</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac stem cells</keyword>
  <keyword>c-kit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

